BBTXBambusa Therapeutics

Bambusa Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation (“I&I”) and fundamentally improve patient quality of life. Our lead product candidate, BBT001, a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated pathways, interleukin-4 receptor alpha and interleukin-31, is designed to simultaneously address core Type 2 inflammation and chronic itch, the...